<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865109</url>
  </required_header>
  <id_info>
    <org_study_id>232-SM-901</org_study_id>
    <nct_id>NCT02865109</nct_id>
  </id_info>
  <brief_title>Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)</brief_title>
  <official_title>Expanded Access Program (EAP) to Provide Nusinersen to Patients With Infantile-onset Spinal Muscular Atrophy (SMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <brief_summary>
    <textblock>
      To provide access to nusinersen to eligible patients with Infantile-onset Spinal Muscular
      Atrophy (SMA) (consistent with Type 1) to address a high-unmet medical need.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The nusinersen expanded access program (EAP) is available at approved treatment centers in
      select territories.

      A doctor must decide whether nusinersen treatment is appropriate for each patient, based on
      the patient's medical history and program eligibility criteria. A full list of participating
      treatment centers is provided in the 'Contacts and Locations' section of this listing, and is
      regularly updated.

      Following local approval and official reimbursement of nusinersen in each territory, the EAP
      will close and patients will transfer to commercially available drug.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Infantile-onset Spinal Muscular Atrophy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nusinersen</intervention_name>
    <description>Administered by intrathecal injection</description>
    <other_name>ISIS 396443</other_name>
    <other_name>BIIB058</other_name>
    <other_name>Spinraza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or
             compound heterozygote.

          -  Onset of clinical signs and symptoms at ≤ 6 months (180 days) of age, consistent with
             infantile onset, Type I SMA

          -  Patient whose care in the opinion of the treating physician meets, and is expected to
             continue to meet, the guidelines set out in the 2007 Consensus Statement for Standard
             of Care in SMA

        Key Exclusion Criteria:

          -  Patient is qualified to participate in an ongoing clinical trial with nusinersen

          -  Participation in a prior nusinersen study

          -  Previous exposure to nusinersen

          -  History of brain or spinal cord disease that would interfere with the LP procedures or
             CSF circulation

          -  Presence of implanted shunt for the drainage of CSF or implanted CNS catheter

          -  Previous or current participation in a clinical trial with an investigational gene
             therapy for SMA

          -  Participation in a study with an investigational therapy for SMA within 6 months or
             five half-lives of the investigational drug, whichever is the longer, prior to the
             first dose of nusinersen.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <state>Taiwan, Province OF China</state>
        <zip>807</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Taiwan, Province OF China</state>
        <zip>100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin</city>
        <zip>050036</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico Federico Gomez</name>
      <address>
        <city>Mexico city</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Auckland District Health Board ADHB</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei city</city>
        <state>Beitou District</state>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Erciyes University Hospital</name>
      <address>
        <city>Kayseri</city>
        <state>Anatolia</state>
        <zip>38000</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe University</name>
      <address>
        <city>Ankara</city>
        <state>Central Anatolia</state>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Marmara Uni. Research &amp; Educational Hospital</name>
      <address>
        <city>Kadıköy</city>
        <state>Istanbul</state>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Medipol University Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Marmara</state>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Muscular Atrophy</keyword>
  <keyword>SMA</keyword>
  <keyword>SMN</keyword>
  <keyword>SMNRx</keyword>
  <keyword>ISIS-SMNRx</keyword>
  <keyword>ISIS-SMN Rx</keyword>
  <keyword>ISIS 396443</keyword>
  <keyword>ISIS-396443</keyword>
  <keyword>ENDEAR</keyword>
  <keyword>IONIS-SMNRx</keyword>
  <keyword>IONIS-SMN Rx</keyword>
  <keyword>EMBRACE</keyword>
  <keyword>NURTURE</keyword>
  <keyword>IONIS</keyword>
  <keyword>BIOGEN</keyword>
  <keyword>SHINE</keyword>
  <keyword>Nusinersen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

